Journals / İnfeksiyon Dergisi / 2005 / Cilt: 19 - Sayı: 1

Investigation of in vitro interacitons of ampicillin/sulbactam-ciprofloxacin, ampicillin/sulbactam-amikacin, impenem-ciprofloxacin, imipenem-amikacin combinations againts multiple resistant Acinetobacter strains

Çoğul dirençli Acinetobacter kökenlerinde ampisilin/sulbaktam-siprofloksasin, ampisilin/sulbaktam-amikasin, imipenem-siprofloksasin, impenem-amikasin kombinasyonlarının in vitro etkileşimlerinin araştırılması

Pages
107–110
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, combination therapy should be applied and in vitro synergy tests should be performed before starting treatment in muitiresistant /tabefobacferinfections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acinetobacter infections cause treatment failures especially in intensive care units because of multiple antibiotic resistance.
📊
Key Findings & Data:The purpose of this study was to investigate the in-vitro effect of antibiotic combinations on 12 muitiresistant Acinetobacter strains.
💡
Conclusion & Impact:In conclusion, combination therapy should be applied and in vitro synergy tests should be performed before starting treatment in muitiresistant /tabefobacferinfections.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Acinetobacter infections cause treatment failures especially in intensive care units because of multiple antibiotic resistance. The purpose of this study was to investigate the in-vitro effect of antibiotic combinations on 12 muitiresistant Acinetobacter strains. The in vitro synergy of sulbactam-ampicillin + ciprofloxacin (SAM+CIP), sulbactam-ampicillin + amikacin (SAM+AK), imipenem + ciprofloxacin (IMP+CIP) and imipenem + amikacin (IMP+AK) combinations were studied by the checkerboard technique in muitiresistant strains. The highest rates of synergy were detected with SAM+AK (3/12) combination. Indifference was found to be 91.6%, 75%, 75% and 83.3% in SAM+CIP, SAM+AK, IMP+CIP and IMP+AK combinations, respectively. In conclusion, combination therapy should be applied and in vitro synergy tests should be performed before starting treatment in muitiresistant /tabefobacferinfections.

Özet

Çoğul dirençli Acinetobacter infeksiyonları özellikle yoğun bakım ünitelerinde sağaltım güçlüğüne neden olmaktadır. Bu çalışma, çoğul dirençli Acinetobacter kökenlerinde antibiyotik kombinasyonlarının in vitro etkinliklerinin araştırılması amacıyla düzenlenmiştir. Çoğul dirençli 12 Acinetobacter kökeninde sulbaktam-ampisilin + siprofloksasin (SAM+CIP), sulbaktam-ampisilin + amikasin (SAM+AK), imipenem + siprofloksasin (IMP+CIP) ve imipenem + amikasin (IMP+AK) kombinasyonlarının in-vitro sinerjistik etkinliği dama tahtası (checkerboard) yöntemi ile araştırılmıştır. En yüksek sinerji oranı SAM+AK (3/12) kombinasyonunda saptanmıştır. Indiferan etkileşim, SAM+CIP, SAM+AK, IMP+CIP ve IMP+AK kombinasyonlarında sırasıyla ; %91.6, %75, %75 ve %83.3 olarak bulunmuştur. Sonuç olarak, çoğul dirençli Acinetobacter infeksiyonlarında kombinasyon sağaltımı ve öncesinde antibiyotik etkileşimlerinin gösterilmesi açısından in vitro sinerji testlerinin yapılması önerilmiştir.

🔖

Cite This Article

TÜRKER, M., AFŞAR, İ., ŞENER, A. G., TÜRK, M. (2022). Investigation of in vitro interacitons of ampicillin/sulbactam-ciprofloxacin, ampicillin/sulbactam-amikacin, impenem-ciprofloxacin, imipenem-amikacin combinations againts multiple resistant Acinetobacter strains. İnfeksiyon Dergisi, Cilt: 19 - Sayı: 1, 107–110. https://ajindex.com/articles/651735

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Shaes DM, Rice LB. Antimicrobiol resistance in hospital flora and nosocomial infections. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. Baltimore: Williams & Wilkins, 1996: 980-99
  2. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999; 27 (Suppl 2): 24-8
  3. Gür D, ed. National Committee for Clinical Standards: Antimikrobik duyarlılık testleri için uygulama standartları. Onikinci bilgi eki M100-S12. Ankara: Bilimsel Tıp Yayınevi, 2002; 22: 94
  4. Moody J. Synergism testing; broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: ASM Press, 1992: 5.18.1-5.18.28
  5. Brauernfeind A, Kljuar S Jungwirth R. Overview of antibiotic resistance problems in Acinetobacter spp. J Med Microbiol 1997; 46: 726-8
  6. Hsueh PR, Liu YC, Yand D, et al. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Drug Resist 2001; 7: 373-82
  7. Afzal MS, Livermore D. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998; 41: 576-7
  8. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329-32
  9. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65
  10. Marques MB, Brookings ES, Moser SA, et al. Comparative in-vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations. Antimicrob Agents Chemother 1997; 41: 881-5
  11. Gould M, Milne K. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxaacin. J Antimicrob Chemother 1997; 39: 53-61
  12. Bouze E, Munoz P. Monotherapy versus combination therapy for bacterial infections. Med Clin North Am 2000; 84: 1357-89
  13. Shokrylanbaran N, Tatman-Otkun M. Nozokomiyal Acinetobacter baumannii kökenlerinde antibiyotik sinerjizmi. İnfek Derg 2002; 16: 463-70
  14. Altoparlak Ü, Özkurt Z Erol S. Nozokomiyal Pseudomonas aeruginosa ve Acinetobacter baumannii suşlarına karşı çeşitli antibiyotik kombinasyonlarının in-vitro etkileşiminin araştırılması. ANKEM Derg 2003; 17: 46-50
  15. Hsueh PR, Ten LJ, Chen CY, et al. Pandrug-resistant Acinetobacter baum